 Sarepta Therapeutics Inc. said it would be delayed at least six months in seeking approval for its lead drug candidate after the U.S. Food and Drug Administration demanded additional information because of concerns about the company’s clinical-trial data.. In Nasdaq trading Monday, the company’s shares sank 32% on news of the delay to $15.91. . Sarepta...
  